Mephenoxalone

Mephenoxalone
Clinical data
Trade names	Dorsiflex, Moderamin, Control-OM
AHFS/Drugs.com	International Drug Names
ATC code	N05BX01 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances);
Identifiers
	IUPAC name 5-[(2-methoxyphenoxy)methyl]-1,3-oxazolidin-2-one;
CAS Number	70-07-5 ;
PubChem CID	6257;
ChemSpider	6021 ;
UNII	CZ87T54W8W;
KEGG	D07318 ;
ChEMBL	ChEMBL2104790 ;
CompTox Dashboard (EPA)	DTXSID9023255 ;
ECHA InfoCard	100.000.658
Chemical and physical data
Formula	C11H13NO4
Molar mass	223.228 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2OC(COc1c(OC)cccc1)CN2;
	InChI InChI=1S/C11H13NO4/c1-14-9-4-2-3-5-10(9)15-7-8-6-12-11(13)16-8/h2-5,8H,6-7H2,1H3,(H,12,13) ; Key:ZMNSRFNUONFLSP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Mephenoxalone (trade names Dorsiflex, Moderamin, Control-OM) is a muscle relaxant^[2] and mild anxiolytic.^[3] It inhibits neuron transmission, relaxing skeletal muscles by inhibiting the reflex arc. As the effect of muscle relaxation, mephenoxalone affects mental condition, and is also a treatment for nervousness and anxiety.

References

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Magnenat M (December 1961). "[The utilization in psychotherapy of a tensiolytic agent with muscle relaxant effect, Control OM (mephenoxalone), alone or associated with thymoleptics]". Therapeutische Umschau. Revue Therapeutique. 18: 516–20. PMID 14468333.
^ MIMS: Mephenoxalone

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] Magnenat M (December 1961). "[The utilization in psychotherapy of a tensiolytic agent with muscle relaxant effect, Control OM (mephenoxalone), alone or associated with thymoleptics]". Therapeutische Umschau. Revue Therapeutique. 18: 516–20. PMID 14468333.

[3] MIMS: Mephenoxalone

[1]

[2]

[3]

Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol, atenolol, betaxolol, nadolol, oxprenolol, pindolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine (tobacco) Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

See also

References